• Intellia Therapeutics reported third quarter 2026 and year to date net losses while advancing its pipeline, and separately released updated clinical and regulatory milestones for its one time CRISPR therapies lonvo z in hereditary angioedema and nex z in transthyretin amyloidosis.
• The combination of a priority FDA review for lonvo z and completion of Phase 3 enrollment for nex z highlights how Intellia Therapeutics is moving from a pure R&D story toward potential commercial execution in two high cost rare disease markets.
• This article reviews how Intellia Therapeutics’ investment narrative is being shaped by lonvo z’s priority FDA review and its reported HAE clinical data.

Scan beyond Intellia Therapeutics and line up other…